Advanced search
Publication Cover
Leukemia & Lymphoma Volume 38, 2000 - Issue 1-2
Submit an article Journal homepage
40
Views
8
CrossRef citations to date
0
Altmetric
Original Article

Phase I/II Trial of Multiple Dose 131Iodine-MAb LL2 (CD22) in Patients with Recurrent Non-Hodgkin's Lymphoma

Julie M. Vose Department of Internal Medicine, 987680, Nebraska Medical Center, Omaha, Nebraska, 68198–7680, USACorrespondence[email protected]
,
David Colcher Department of Internal Medicine, 987680, Nebraska Medical Center, Omaha, Nebraska, 68198–7680, USA
,
Lisa Gobar Department of Internal Medicine, 987680, Nebraska Medical Center, Omaha, Nebraska, 68198–7680, USA
,
Philip J. Bierman Department of Internal Medicine, 987680, Nebraska Medical Center, Omaha, Nebraska, 68198–7680, USA
,
Samuel Augustine Department of Internal Medicine, 987680, Nebraska Medical Center, Omaha, Nebraska, 68198–7680, USA
,
Margaret Tempero Department of Internal Medicine, 987680, Nebraska Medical Center, Omaha, Nebraska, 68198–7680, USA
,
Peter Leichner Department of Internal Medicine, 987680, Nebraska Medical Center, Omaha, Nebraska, 68198–7680, USA
,
James C. Lynch Department of Internal Medicine, 987680, Nebraska Medical Center, Omaha, Nebraska, 68198–7680, USA
,
David Goldenberg Department of Internal Medicine, 987680, Nebraska Medical Center, Omaha, Nebraska, 68198–7680, USA
&
James O. Armitage Department of Internal Medicine, 987680, Nebraska Medical Center, Omaha, Nebraska, 68198–7680, USA
 show all
Pages 91-101 | Received 08 Jun 1999, Accepted 10 Nov 1999, Published online: 01 Jul 2009

References

  • Velasquez W S, McLaughlin P, Tucker S, et al. ESHAP - An Effective Chemotherapy Regimen in Refractory and relapsing lymphoma: A 4–year follow-up study. J Clin Oncol 1994; 12: 1169–1176
  • Cabanillas F, Hagemeister F B, Bodey G P, Freireich E J. IMVP-16 An effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 1982; 60: 693–697
  • Gallagher C J, Gregory W M, Jones A E, et al. Follicu-lar lymphoma prognostic factors for response and survival. J CIin Oncol 1986; 4: 1470–1474
  • Paryani S B, Hoppe R T, Cox R S, et al. Analysis of non-Hodgkin's lymphomas with nodular and favourable histologies, stages I and II. Cancer 1983; 52: 2300–2305
  • Rohatiner A ZS, Johnson P WM, Price C GA, et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 1994; 12: 1177–1184
  • Bierman P J, Vose J M, Anderson J R, et al. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 445–450
  • Hokland P, Ritz J, Schlosman S F, Nadler L M. Orderly expression of B-cell antigens during the in vitro differentiation of nonmalignant human pre-B cells. J Immunol 1985; 135: 1746–1751, 1985
  • Stashenko P, Nadler L M, Hardy R, et al. Characterization of a human B-lymphocyte specific antigen. J Immunol 1980; 125: 1678–1685
  • Pawlak-Byczkowska E J, Hansen H J, Dion A S, et al. Two new monoclonal antibodies, EP B-1 and EPB-2, reactive with human lymphoma. Cancer Res 1989; 49: 4568–4577
  • Goldenberg D M, Horowitz J A, Sharkey R M, et al. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131 labeled LL2 monoclonal antibody. J Clin Oncol 1991; 9: 548–564
  • Vose J M, Anderson J R, Kessinger A, et al. High-dose chemotherapy and autologous hematopoietic stem cell transplantation for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 1846–1850
  • Hunter W M, Greenwood F C. Preparations of iodine-131 labelled human growth hormone of high specific activity. Nature: 1962; 194: 495–496
  • Bigler R, Zanzonico P B, Leonard R, et al. Bone marrow dosimetry for monoclonal antibody therapy. Proceedings of the 4th International Radiopharmaceutical Dosimetry Symposium. Oak Ridge National Laboratory, Oak Ridge, TN 1985; 535–544
  • Loevinger R, Berman M. A revised scheme for calculating the absorbed dose from biologically distributed radionuclide. Medical Internal Radiation Dose, Pamphlet I. Society of Nuclear Medicine, Inc, New York 1976
  • Davis T A, Maloney D G, Liles T M, et al. Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. Blood 1998; 92: 1184–1190
  • McLaughlin P, Grillo-Lopez A J, Link B K, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833
  • Kaminski M S, Zasadny K R, Francis I R, et al. Radioimmuno-therapy of B-cell lymphoma with [131I] Anti-B1 (Anti-CD20) antibody. N Engl J Med 1993; 329: 459–465
  • Vose J M, Saleh M, Lister A, et al. Iodine-131 anti-B1 antibody for non-Hodgkin's lymphoma: overall clinical trail experience. Proc ASCO 1998; 17: 38a
  • Press O W, Eary J F, Appelbaum F R, et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B-cell lymphomas. Lancet 1995; 346: 336–340
  • Knox S J, Goris M L, Strider K, et al. Yttrium-90–labeled Anti-CD20 Monoclonal Antibody therapy of recurrent B-cell lymphoma. Clinical Cancer Res 1996; 2: 457–470
  • White C A, Halpern S E, Parker B A, et al. Radioimmuno-therapy of relapsed B-cell lymphoma with yttrium 90 Anti-idiotype monoclonal antibodies. Blood 1996; 87: 3640–3649
  • Shih L B, Lu H HZ, Xuan H, Goldenberg D M. Internali-zation and intracellular processing of an anti-B-cell lymphoma monoclonal antibody, LL2. Int J Cancer 1994; 56: 538–545
  • Duncan J R, Welch M J. Intracellular metabolism of indium-111–DTPA-labeled receptor targeted proteins. J Nucl Med 1993; 34: 1728–1738
  • Behr T M, Sharkey R M, Juweid M, et al. Residualizing (indium, yttrium) versus released (iodine) isotopes in radio-immunodetection and therapy with internalizing antibodies (Abstract). J Nucl Med 1995; 36: 20

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.